证券日报网讯金凯生科（301509）10月22日在互动平台回答投资者提问时表示，截至2025年10月20日， 公司股东数为13781户。 ...

证券日报网讯金凯生科（301509）10月10日在互动平台回答投资者提问时表示，截至2025年9月30日， 公司股东数为14088户。 ...

（编辑 袁冠琳） 证券日报网讯 金凯生科10月9日在互动平台回答投资者提问时表示，公司主营小分子CDMO服务，在中 美两地均设有生产基地，相关关税政策目前对公司业务没有影响，公司生产经营正常；三季度业绩具体 情况请投资者关注公司三季度报告。 ...

证券日报网讯金凯生科（301509）10月9日在互动平台回答投资者提问时表示，公司主营小分子CDMO 服务，在中美两地均设有生产基地，相关关税政策目前对公司业务没有直接影响；公司产品以出口为 主，会持续关注关税政策的相关影响，目前公司生产经营正常。 ...

Core Viewpoint - The company, Jinkai (Liaoning) Life Science Technology Co., Ltd., is engaged in providing custom R&D and production services for small molecule drug intermediates and a small amount of raw materials for global innovative pharmaceutical companies, with a focus on fluorinated and non-fluorinated CDMO businesses [2][8]. Business Overview - The main products of the company include fluorinated CDMO services and non-fluorinated CDMO services [2]. - As of the 2024 annual report, overseas revenue accounts for 61.18% of total revenue, benefiting from the depreciation of the RMB [4]. - The company has a project for producing high-end pharmaceutical products, including intermediates for Semaglutide oral formulations [2][3]. Financial Performance - For the first half of 2025, the company achieved operating revenue of 348 million yuan, representing a year-on-year growth of 32.98%, and a net profit attributable to shareholders of 71.76 million yuan, up 123.61% year-on-year [8]. - The company has distributed a total of 117 million yuan in dividends since its A-share listing [9]. Market Activity - On September 26, the company's stock price fell by 2.02%, with a trading volume of 64.12 million yuan and a turnover rate of 3.17%, bringing the total market capitalization to 4.272 billion yuan [1]. - The stock has shown no significant trend in major capital inflows, with a net outflow of 8.2 million yuan on the day [5][6]. Technical Analysis - The average trading cost of the stock is 39.14 yuan, with recent accumulation activity noted, although the strength of this accumulation is weak [7]. - The stock price is approaching a resistance level of 36.40 yuan, indicating potential for a pullback unless this level is broken [7].

（一）启鹭投资 1、减持股份来源：首次公开发行前持有的公司股份（含该等股份上市后资本公 积金转增股本取得的股份）。 证券代码：301509 证券简称：金凯生科 公告编号：2025-036 金凯（辽宁）生命科技股份有限公司 关于股东减持股份计划期间届满暨减持结果的公告 股东启鹭（厦门）股权投资合伙企业（有限合伙）、青岛青松创业投资集团 有限公司－青岛松凯创业投资企业（有限合伙）保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 金凯（辽宁）生命科技股份有限公司（以下简称"公司"）于近日分别收到股东 启鹭（厦门）股权投资合伙企业（有限合伙）（以下简称"启鹭投资"）、青岛青松 创业投资集团有限公司－青岛松凯创业投资企业（有限合伙）（以下简称"青松投 资"）提交的《关于减持金凯（辽宁）生命科技股份有限公司股份计划期间届满暨减 持结果告知函》，截至本报告披露日，前述股东本次减持计划期限届满。现将有关情 况公告如下： 一、股东减持情况 2、股东减持股份情况 | 股东名称 | 减持方式 | | 减持期间 | 减持均价（元 | ...

Core Viewpoint - The company, Jinkai (Liaoning) Life Science Technology Co., Ltd., is engaged in providing custom research and production services for small molecule drug intermediates and a small amount of raw materials for global pharmaceutical companies, with a focus on fluorinated and non-fluorinated CDMO businesses [2][8]. Business Overview - The main products of the company include fluorinated CDMO services and non-fluorinated CDMO services [2]. - As of the 2024 annual report, overseas revenue accounted for 61.18% of total revenue, benefiting from the depreciation of the RMB [4]. - The company has a project for the production of high-end pharmaceutical products, including intermediates for Semaglutide oral formulations [2][3]. Financial Performance - For the first half of 2025, the company achieved operating revenue of 348 million yuan, a year-on-year increase of 32.98%, and a net profit attributable to the parent company of 71.76 million yuan, a year-on-year increase of 123.61% [8]. - The company has distributed a total of 117 million yuan in dividends since its A-share listing [9]. Market Activity - On September 25, the company's stock price increased by 0.08%, with a trading volume of 84.12 million yuan and a turnover rate of 4.07%, bringing the total market capitalization to 4.36 billion yuan [1]. - The main net inflow of funds today was 6.39 million yuan, with no significant trend in the main force's position [5][6]. Technical Analysis - The average trading cost of the stock is 39.25 yuan, with recent rapid outflows of chips, suggesting a potential recommendation for portfolio adjustment [7].

Core Viewpoint - The company JinKai Life Science has shown a positive market performance with a 1.46% increase in stock price, reaching a market capitalization of 4.357 billion yuan, while its main business focuses on providing custom R&D and production services for small molecule drug intermediates and a small amount of raw materials for global pharmaceutical companies [1][8]. Business Overview - The company's main business involves providing custom R&D and production services for small molecule drug intermediates and a limited amount of raw materials for global innovative pharmaceutical companies [2][8]. - JinKai's primary products include fluorinated CDMO services and non-fluorinated CDMO services [2]. - The company has a significant focus on Alzheimer's-related intermediates and has established capabilities in fluorination processes [3][4]. Financial Performance - For the first half of 2025, JinKai achieved a revenue of 348 million yuan, representing a year-on-year growth of 32.98%, and a net profit attributable to shareholders of 71.76 million yuan, which is a 123.61% increase compared to the previous year [8]. - The company's overseas revenue accounted for 61.18% of total revenue, benefiting from the depreciation of the Chinese yuan [4]. Market Activity - The stock has experienced a net outflow of 2.1341 million yuan from major investors today, indicating a trend of reduced holdings over the past three days [5][6]. - The average trading cost of the stock is 39.38 yuan, with the current price approaching a resistance level of 36.40 yuan, suggesting potential for upward movement if this level is surpassed [7]. Shareholder Information - As of September 19, the number of shareholders in JinKai decreased by 3.65% to 14,300, with an average of 3,968 circulating shares per person, reflecting a slight increase of 3.78% [8]. - The company has distributed a total of 117 million yuan in dividends since its A-share listing [9]. Institutional Holdings - As of June 30, 2025, two major funds exited the top ten circulating shareholders list, indicating potential shifts in institutional interest [10].

Company Overview - Jinkai (Liaoning) Life Science Technology Co., Ltd. is located in Fuxin City, Liaoning Province, and was established on June 8, 2009. The company went public on August 3, 2023. Its main business involves providing small molecule CDMO services to global clients in the life sciences sector, assisting pharmaceutical companies with new drug development projects by offering custom development and production services for small molecule drug intermediates and a limited amount of active pharmaceutical ingredients [2]. Financial Performance - For the period from January to June 2025, Jinkai Life Science achieved operating revenue of 348 million yuan, representing a year-on-year growth of 32.98%. The net profit attributable to the parent company was 71.76 million yuan, showing a significant increase of 123.61% compared to the previous year [2]. Shareholder Information - As of September 19, 2025, the number of shareholders in Jinkai Life Science was 14,300, a decrease of 3.65% from the previous period. The average circulating shares per person increased by 3.78% to 3,968 shares [2]. Financing and Trading Activity - On September 23, Jinkai Life Science's stock price fell by 2.46%, with a trading volume of 105 million yuan. The margin trading data indicated a financing purchase amount of 9.33 million yuan and a repayment of 9.64 million yuan, resulting in a net financing outflow of 308,900 yuan. The total margin balance as of September 23 was 140 million yuan, accounting for 6.91% of the circulating market value, which is above the 80th percentile level over the past year [1]. Dividend Distribution - Since its A-share listing, Jinkai Life Science has distributed a total of 117 million yuan in dividends [3]. Institutional Holdings - As of June 30, 2025, two funds, Yuanxin Yongfeng Ju You A and Yuanxin Yongfeng Xing Yuan A, have exited the list of the top ten circulating shareholders of Jinkai Life Science [3].

Group 1 - The company, Jinkai Biotechnology (301509), reported that as of September 19, 2025, the number of shareholders is 14,299 [1]